Supraventricular Tachycardia (SVT) is a type of irregular heartbeat seen when the heart's upper chambers beat either too quickly or out of rhythm with the heart's lower chambers. The loss of synchronization between the upper and lower chambers will result in perturbations of, blood flow. This is why SVT, which includes atrial fibrillation and atrial flutter, is a leading cause of strokes, heart attacks, and heart failure in the world today. The most successful treatment for SVT is catheter ablation, a procedure in which an electrophysiologist (EP) maps the heart to find areas with abnormal electrical activity. The EP then runs a catheter into the heart to ablate the abnormal areas, blocking the electrical signals or destroying the myocytes causing them. Not much is known about what triggers SVT and much research is still being done to find effective ablation strategies for various forms of SVT. We have produced a dynamic model of the left atrium accelerated on NVIDIA GPUs. An interface allows researchers to insert ectopic signals into the simulated atrium and ablate sections of the atrium allowing them to rapidly gain insight into what causes SVT and how to terminate them.

The authors have declared no competing interest.

The NVIDIA corporation supported the project with hardware donations through their NVIDIA Applied Research Accelerator Program. Summer salaries were provided by the President's Excellence in Research Scholars program.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

No data produced